ENTRÉE Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced/Recurrent NSCLC
A new immune-boosting antibody added to chemotherapy did not improve survival in previously treated lung cancer despite acceptable safety.
The ENTRÉE Lung Sub-study 1 Phase 2 RCT found no survival benefit for feladilimab (an ICOS costimulatory agonist antibody) added to docetaxel in second-line NSCLC post-checkpoint therapy, with numerically worse OS (HR 1.5). Despite an acceptable safety profile, this negative result suggests ICOS agonism alone is insufficient to overcome resistance to prior anti-PD(L)1 therapy in this setting.
What the study was
- Study design
- Phase 2 open-label randomized platform trial sub-study
- Population
- Advanced/recurrent NSCLC patients who progressed on prior anti-PD(L)1 + platinum chemo (n=105)
- Sample size
- 105
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Clinical Lung Cancer
Why it surfaced
Negative Phase 2 RCT with direct clinical relevance for immunotherapy strategies in NSCLC. Informs against ICOS monotherapy approaches in post-checkpoint failure setting.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.